Date: 2015-02-19
Type of information: Development agreement
Compound: bispecific antibodies targeting immune checkpoints
Company: Genmab (Denmark) Bionovion (The Netherlands)
Therapeutic area: Cancer - Oncology
Type agreement: development commercialisation
Action mechanism: bispecific antibody
Disease:
Details: * On February 19, 2015, Genmab announced it has entered a co-development and commercialization agreement with BioNovion to evaluate a number of DuoBody product candidates targeting immune checkpoints. Genmab and BioNovion will contribute panels of antibodies for the creation of bispecific antibody products using Genmab\'s DuoBody platform technology. If the companies jointly select a product candidate for clinical development, development costs will be shared equally, with each party retaining a 50% share of the product rights. If one of the companies decides not to move a therapeutic candidate forward, the other company is entitled to continue developing the product at predefined licensing terms. The agreement also includes terms which allow the parties to opt out of joint development at key points in each product\'s clinical development. This commercial agreement follows a July 2014 research collaboration between Genmab and BioNovion.
Financial terms:
Latest news:
